Education
About Us
Working with TipRanks
Follow Us
SMRI - ETF AI Analysis
Top Page
Bushido Capital US Equity ETF (SMRI)
Rating:73Outperform
Price Target:
$38.00
Positive Factors
Strong Top Holdings
Several top holdings, such as Dell Technologies and Cardinal Health, have delivered strong year-to-date performance, supporting the ETF's overall returns.
Sector Diversification
The ETF is spread across multiple sectors, including Technology, Energy, and Health Care, which helps balance risks from sector-specific downturns.
Steady Performance
The ETF has shown consistent positive returns year-to-date and over the past three months, indicating solid momentum.
Negative Factors
High Expense Ratio
The ETF charges a relatively high expense ratio compared to many other funds, which can eat into investor returns over time.
Over-Concentration in U.S. Market
With nearly all assets invested in U.S. companies, the ETF lacks geographic diversification and is vulnerable to domestic market risks.
Mixed Performance Among Holdings
Some top holdings, such as Merck & Company and Elevance Health, have underperformed year-to-date, potentially dragging on overall returns.
SMRI vs. SPDR S&P 500 ETF (SPY)
AUM477.80M
RegionNorth America
Expense Ratio0.72%
Beta0.82
IssuerBushido
Inception DateSep 14, 2023
Dividend Yield0.43%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume6,122
30 Day Avg. Volume12,889
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
41.01Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering47
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SMRI Summary
The Bushido Capital US Equity ETF (Ticker: SMRI) is a fund that invests in a wide range of U.S. companies, focusing on stocks that are undervalued but have strong growth potential. It includes businesses from various sectors like technology, energy, and healthcare, with well-known companies such as Dell Technologies and Merck & Company among its top holdings. This ETF is ideal for investors looking for long-term growth and diversification across the U.S. market. However, new investors should be aware that its performance can fluctuate with the overall market, and its focus on value stocks may mean slower returns in the short term.
How much will it cost me?The Bushido Capital US Equity ETF (Ticker: SMRI) has an expense ratio of 0.72%, meaning you’ll pay $7.20 per year for every $1,000 invested. This is higher than average because it is actively managed, which typically involves more research and decision-making compared to passively managed funds that track an index.
What would affect this ETF?The Bushido Capital US Equity ETF (SMRI) could benefit from growth in the technology and healthcare sectors, which make up a significant portion of its holdings, especially if innovation and demand in these areas continue to rise. However, potential risks include economic downturns or rising interest rates, which could negatively impact value stocks and sectors like energy and consumer cyclical. Regulatory changes or geopolitical tensions affecting U.S. markets may also influence the ETF's performance.
SMRI Top 10 Holdings
The Bushido Capital US Equity ETF leans heavily into technology and energy, with names like Dell Technologies and Cisco Systems providing steady growth thanks to their focus on AI and innovation. Newmont Mining has been a standout performer, riding strong cash flows and strategic initiatives in the materials sector. On the flip side, Merck is lagging, weighed down by competitive pressures and slowing revenue growth in healthcare. With its U.S.-focused portfolio and a value-driven approach, the fund balances rising stars with a few underperformers, offering a disciplined yet diverse exposure to the market.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Cardinal Health | 2.88% | $13.78M | $48.39B | 68.94% | 65 Neutral | |
| Incyte | 2.75% | $13.14M | $20.81B | 27.10% | 81 Outperform | |
| Regeneron | 2.51% | $12.01M | $69.11B | -20.63% | 79 Outperform | |
| Royalty Pharma | 2.49% | $11.89M | $22.26B | 47.12% | 80 Outperform | |
| Coterra Energy | 2.48% | $11.86M | $20.23B | 8.10% | 73 Outperform | |
| Expand Energy | 2.45% | $11.70M | $26.78B | 21.58% | 65 Neutral | |
| United Parcel | 2.44% | $11.64M | $81.46B | -27.55% | 72 Outperform | |
| Dell Technologies | 2.43% | $11.61M | $98.64B | 9.29% | 65 Neutral | |
| Renaissancere Holdings | 2.43% | $11.59M | $12.42B | 0.50% | 79 Outperform | |
| Merck & Company | 2.38% | $11.35M | $214.15B | -16.17% | 78 Outperform |
SMRI Technical Analysis
Positive
―
Price Trends
34.50
Positive
33.63
Positive
32.30
Positive
Market Momentum
0.15
Negative
57.81
Neutral
68.09
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For SMRI, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 34.65, equal to the 50-day MA of 34.50, and equal to the 200-day MA of 32.30, indicating a bullish trend. The MACD of 0.15 indicates Negative momentum. The RSI at 57.81 is Neutral, neither overbought nor oversold. The STOCH value of 68.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SMRI.
SMRI Peer Comparison
Comparison Results
Performance Comparison
SMRI
Bushido Capital US Equity ETF
35.10
2.56
7.87%
SYLD
Cambria Shareholder Yield ETF
―
―
―
PLDR
Putnam Sustainable Leaders ETF
―
―
―
ABFL
Fcf Us Quality Etf
―
―
―
BGDV
Bahl & Gaynor Dividend ETF
―
―
―
EBI
Longview Advantage ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents